Medifast, Inc. reported Q4 2025 revenue of $75.1 million and net loss of $18.1 million including a $12.1 million non-cash valuation allowance, with full year 2025 revenue of $385.8 million and net loss of $18.7 million. The company provided Q1 and full year 2026 guidance and highlighted a strong balance sheet with $167.3 million in cash and no debt.
Key takeaways
Q4 2025 revenue $75.1 million, down 36.9% from $119.0 million in Q4 2024
Q4 2025 net loss $18.1 million or ($1.65) diluted EPS including $12.1 million valuation allowance
Full year 2025 revenue $385.8 million, down 36.0% from $602.5 million in 2024
Active earning coaches 16,100 in Q4 2025, down 40.6% from 27,100 in Q4 2024
Cash, cash equivalents, and investment securities $167.3 million as of Dec 31, 2025, no debt
2026 guidance: Q1 revenue $65-80 million, full year revenue $270-300 million